Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
11/1999
11/02/1999US5977313 Nondegraded active fibrinogen or fragments bound to insoluble carrier; anticarcinogenic/antitumor/antimetastasis agents to remove circulating metastatic tumour cells, or suppress deposition in vessels; treatment of thrombocytopenia
11/02/1999US5977310 Polyethylene glycol modified hepatocyte growth factor; prolonged clearance in vivo with same physiological activity; for reduced dosage with reduced side effects; viricides; anticarcinogenic agents; treatment of liver/kidney disorders
11/02/1999US5977307 Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
11/02/1999US5977180 Anandamide analog compositions and method of treating intraocular hypertension using same
11/02/1999US5977175 Methods and compositions for improving digestion and absorption in the small intestine
11/02/1999US5977164 Antitumor
11/02/1999US5977163 Water soluble paclitaxel prodrugs
11/02/1999US5977127 Water soluble stabilizing acid additive whose pks value falls within a given range, such as citric acid or absorbic acid in specific molar ratio
11/02/1999US5977109 Sacchrides, storage stability, antitumor
11/02/1999US5977087 Topical preparation for treatment of aphthous ulcers and other lesions
11/02/1999US5977084 Self-assembling polynucleotide delivery method
11/02/1999US5977082 Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
11/02/1999US5977081 Triterpene saponin analogs having adjuvant and immunostimulatory activity
11/02/1999US5977076 Carrier coupled to dipetide; antiinflammatory agents; grafting tissue
11/02/1999US5977071 Complexes; antidiabetic agent
11/02/1999US5977070 Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
11/02/1999US5977069 Mixture of growth hormone and asparagine as stabilizer
11/02/1999US5977068 Parenteral administering
11/02/1999US5977066 Oral administering mixture containing glycerides and reaction product of hydrogenated castor oil and ethylene glycol
11/02/1999US5976604 Mixture of sucrose fatty acid ester, water and oil
11/02/1999US5976578 Mixture of antacid, preservative, buffer in aqueous vehicle
11/02/1999US5976577 Process for preparing fast dispersing solid oral dosage form
11/02/1999US5976576 Active material is n-4-(1h-tetrazol-5-yl)phenyl-4-(1h-tetrazol-5-yl)benzamide, disodium salt
11/02/1999US5976574 Forming a suspension; spray drying
11/02/1999US5976573 Aqueous-based pharmaceutical composition
11/02/1999US5976571 Method for making a multi-stage drug delivery system
11/02/1999US5976569 Diketopiperazine-based delivery systems
11/02/1999US5976566 Non-steroidal antiinflammtory drug formulations for topical application to the skin
11/02/1999US5976561 The principal ingredient is benzalkonium chloride in a water soluble gel which includes sorbitol, glycerin, hydroxethylcellulose and propylene glycol.
11/02/1999US5976560 Products suitable for application to the skin. it is comprised ofvegetable oil and silica.
11/02/1999US5976547 Extract of arnica montana in combination with menthol crystal, camphor, oil of mint, eucalyptus oil, guaifenesin, lidocaine blended in either a pluronic lecithin organogel or a petrolatum base.
11/02/1999US5976538 Adjuvant composition containing synthetic hydrophobic lipopolysaccharide
11/02/1999US5976535 Pretargeting protocols for the enhanced localization of cytotoxins to target sites and cytotoxic combinations useful therefore
11/02/1999CA2053911C Recombinant antibody-toxin fusion protein
10/1999
10/28/1999WO1999054457A1 Vaccine formulations comprising antiidiotypic antibodies which immunologically mimic group b streptococcal carbohydrates
10/28/1999WO1999054456A1 ANTISENSE OLIGONUCLEOTIDES FOR THE INHIBITION OF INTEGRIN αv-SUBUNIT EXPRESSION
10/28/1999WO1999053969A1 Preparation for regenerating collagen
10/28/1999WO1999053958A2 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
10/28/1999WO1999053957A1 Estradiol-containing percutaneous absorption preparations
10/28/1999WO1999053954A1 Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation
10/28/1999WO1999053951A1 Terminally-branched polymeric linkers and polymeric conjugates containing the same
10/28/1999WO1999053941A1 Oral preparations containing trh derivatives
10/28/1999WO1999053923A1 Pharmaceutical composition
10/28/1999WO1999053920A1 Use of vitamin pp compounds
10/28/1999WO1999053908A2 Pro-drug conjugates for the treatment of stroke and other ischaemic conditions
10/28/1999WO1999053901A1 Pharmaceutical aerosol formulation
10/28/1999WO1999053900A1 Drug delivery of proteins from polymeric blends
10/28/1999WO1999053899A1 Medicinal compositions for application to mucosa
10/28/1999WO1999053898A1 Implants for administering substances and methods of producing implants
10/28/1999WO1999053754A1 Subversion of bacterial resistance by low solubility antibiotics
10/28/1999WO1999040112A9 Neuroprotective peptides and uses thereof
10/28/1999WO1999039740A3 Sensitizing cells to compounds using lipid-mediated gene and compound delivery
10/28/1999WO1999039691A3 Pharmaceutical compositions
10/28/1999WO1999037282A3 Reduced lipid flowable cosmetic or dermatological preparations
10/28/1999WO1999034832A8 Crystallographically stable amorphous cephalosporin compositions and process for producing the same
10/28/1999DE19818802A1 Stable mitoxantron solutions useful for cancer therapy
10/28/1999DE19818044A1 Reducing side effects or neutralizing action of carcinostatic or immunosuppressive agents, especially pyridine derivatives, using vitamin PP compounds, e.g. nicotinamide
10/28/1999CA2328882A1 Pharmaceutical aerosol formulation
10/28/1999CA2328081A1 Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with prostaglandin inhibitor
10/28/1999CA2325821A1 Antisense oligonucleotides for the inhibition of integrin .alpha.v-subunit expression
10/28/1999CA2320135A1 Preparation for regenerating collagen
10/27/1999EP0952171A2 Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof
10/27/1999EP0951560A1 Conjugates of a particle vector and oligonucleotides, process for their preparation, and pharmaceutical compositions containing them
10/27/1999EP0951484A2 Colon cancer kh-1 and n3 antigens
10/27/1999EP0951478A1 Polysaccharide-peptide derivatives
10/27/1999EP0951472A1 Peptide compositions with growth factor-like activity
10/27/1999EP0951300A1 Processes for spray drying solutions of hydrophobic drugs with hydrophilic excipients and compositions prepared by such processes
10/27/1999EP0951294A1 Wound healing formulations containing human plasma fibronectin
10/27/1999EP0951287A2 Oral composition comprising 5-aminosalicyclic acid
10/27/1999CN1233288A GnRH-leukotoxin chimeras
10/27/1999CN1233189A Treatment of asthma with TNFR-Ig
10/27/1999CN1233170A Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
10/27/1999CN1233169A Process for the manufacture of a pulverous preparation
10/27/1999CN1233149A Method of making controlled release devices
10/27/1999CN1045892C Chinese medicine preparation for preventing and curing coronary heart disease and angina pectoris
10/27/1999CN1045884C High dose formulations containing active agent
10/26/1999US5973116 Compounds for targeting
10/26/1999US5973069 Polyethylene oxides having saccharide residue at one end and different functional group at another end
10/26/1999US5973040 Tetramethylpiperidine-containing copolymers
10/26/1999US5972992 Comprising taxol and a pharmaceutically-acceptable carrier wherein said pharmaceutical taxol composition has a ph less than or equal to 7; improved stability
10/26/1999US5972967 Intravenous administering 2-(butylsulfonylamino)-3-(4-(4-(piperidin-4-yl)butoxyphenyl)pr opionic acid
10/26/1999US5972912 Dissolving an oxazaphosphorin in water, adding an amino acid to the solution to produce a mixture and lyophilizing the mixture to remove the water
10/26/1999US5972911 Composition for the delivery of orally administered drugs and other substances
10/26/1999US5972910 Reducing methane production in animals or improving the weight gain of an animal by administering an active materials enclosed in, confined or encapsulated with cyclodextrins
10/26/1999US5972906 Administering topically an effective amount of antiinflammatory agent/non-steroid/ and a form of hyaluronic acid selected from hyaluronic acid or salts
10/26/1999US5972901 Making a composition for delivering an oligonucleotide to a mammalian cell by providing a peptide target binding moiety being capable of binding to a serpin enzyme complex receptor, polylysine, an oligonucleotide vector; conjugating, coupling
10/26/1999US5972900 Conjugating target binding moiety consisting of an antibody or fragment which binds to secretory component of polymeric immunoglobulin receptor on surface of epithelium cell, nucleic acid binder, expression vector, compacting, administering
10/26/1999US5972892 For reducing or eliminating the skin irritant side-effect of a therapeutic composition; a stabilizer for desensitization
10/26/1999US5972891 A mixture comprising an active nonapeptide or decapeptide and a biodegradable polymer having a terminal carboxyl group, showing constant release of the peptide over a long time
10/26/1999US5972889 A conjugate of a polypeptide reactive with a fibroblast growth factor receptor and a cytotoxic agent is used for preventing the proliferation of epithelial lens cells, especially following extracapsular cataract surgery
10/26/1999US5972879 Inhibiting agent against the proliferation of tumor cells
10/26/1999US5972720 Colloidal particles surface are co-adsorbed with biomolecules and polyoxyethylene qlycol substituted by thiol and/or disulfide groups; as detection reagent in an immunoassay
10/26/1999US5972707 Gene delivery system
10/26/1999US5972600 Separation of active complexes
10/26/1999US5972389 Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
10/26/1999US5972388 A sustained release of drug comprising a spray drying hydroxypropyl cellulose powder; a drug delivery by oral inhalation to lower airways
10/26/1999US5972387 Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
10/26/1999US5972384 Particulate, biologically active, ceramic-glass matrix impregnated with one or more microencapsulated therapeutically beneficial drugs forming a ceramodrug matrix, capable of releasing the drugs at a predetermined rate
10/26/1999US5972382 Use of piperine as a bioavailability enhancer
10/26/1999US5972379 Liposomes having a surface coating of hydrophilic polymer chains and an entrapped ciprofloxacin-amino acid conjugate, useful for treating the bacterial infections
1 ... 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 ... 1712